1. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovascular Drug Review 1999; 17 (2): 115–33.
2. DeForrest JM, Waldron TL, Krapcho J et al. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J Cardiovasc Prarmacol 1989; 13 (6): 887–94.
3. Cushman DW, Wang FL, Fung WS et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989; 28: 115–31.
4. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after adminidtration of zofenopril, captopril, and lisinopril. J Cardiovasc Prarmacol 1991; 18 (4): 478–86.
5. Marzo A, Dal Bo L, Mazzucchelli P et al. Pharmacokinetics and pharmacodinamics of zofenopril in healthy volunteers. Arzeimittelforschung 1999; 49: 992–6.
6. Singhvi SM, Foley JE, Wilard DA et al. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79: 970–3.
7. Liu X, Engelman RM, Rousou JA et al. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther, August 1, 1992; 6 (4): 437–43.
8. Sargent CA, Sleph PG, Dzwonczyk S et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J Pharmacol Exp Ther 1993; 265 (2): 609–18.
9. Leva C, Mariscalco G, Ferrarese S et al. The role of zofenopril in myocardial protection during cardioplegia arrest: an isolated rat heart model. J Card Surg 2006; 21 (1): 44–9.
10. Cominacini L, Pasini A, Garbin U et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15 (10 Pt 1): 891–5.
11. Buikema H, Monnink SH, Tio RA et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130 (8): 1999–2007.
12. Borghi C, Bacchelli S, Esposti DD, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Exp Opin Pharmacother 2004; 5 (9): 1965–77.
13. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
14. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27 (3): 371–6.
15. Napoli C, Bruzzese G, Ignarro LJ et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156 (6): 1154.e1–8.
16. Андрущишина Т.Б., Морозова Т.Е., Ошорова С.Д. Эффективность и безопасность зофеноприла у больных артериальной гипертонией в сочетании с ожирением. Материалы XI Всероссийского научно-образовательного форума «Кардиология 2009».
17. Malacco E, Piazza S, Omboni S, and on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25 (3): 175–82.
18. Наркевич К. Сравнение домашнего и офисного артериального давления у пациентов с артериальной гипертонией, леченных зофеноприлом или лозартаном. Пробл. жен. здоровья. 2008; 3 (1): 7–14.
19. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5.
20. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80–7.
21. Westendorp B, Schoemaker RG, van Gilst WH et al. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: Differential effects on lisinopril and zofenopril Eur J Pharmacol 2005; 527 (1–3): 141–9.

Е.Н.Данковцева, Д.А.Затейщиков